<DOC>
	<DOC>NCT02021773</DOC>
	<brief_summary>The purpose of the study is to determine whether monthly subcutaneous administration of LBR-101 is safe and provides migraine prevention in patients with chronic migraine.</brief_summary>
	<brief_title>Assessment of LBR-101 In Chronic Migraine</brief_title>
	<detailed_description>Two distinct doses of subcutaneous LBR-101 administered monthly will be compared to placebo for safety and efficacy. The mean change from baseline in the number of cumulative headache hours measured at the 28-day period ending with week 12.</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>Males or females aged 18 to 65 years of age. A signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study including any known and potential risks and available alternative treatments. Chronic migraine meeting the diagnostic criteria listed in the International Classification of Headache Disorders (ICHDIII beta version, 2013) Body Mass Index (BMI) of 17.5 to 37.5 kg/m2, and a total body weight between 50 kg and 120 kg inclusive. Demonstrated compliance with the electronic headache diary during the runin period headache data on a minimum of 22/28 days (80% diary compliance) Onset of chronic migraine after the age of 50 years. Subject has received onabotulinum toxin A for migraine or for any medical or cosmetic reasons requiring injections in the head, face, or neck during the 6 months prior to study entry. Subject is using medications containing opioids (including codeine) or barbiturates (including Fiorinal®, Fioricet®, or any other combination containing butalbital) on more than 4 days per month for the treatment of migraine or for any other reason. Failed &gt; 2 medication categories or &gt; 3 preventive medications (within two medication categories) due to lack of efficacy for prophylactic treatment of episodic or chronic migraine after an adequate therapeutic trial Treatment with an investigational drug or device within 30 days of study entry or any prior exposure to a monoclonal antibody targeting the CGRP pathway.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Headache</keyword>
	<keyword>Migraine</keyword>
	<keyword>Chronic Migraine</keyword>
</DOC>